Print

Ipsen (IPN.PA) Initiates a Phase II "Switch Maintenance" Trial in Metastatic Castrate-Resistant Prostate Cancer With Tasquinimod  
10/3/2012 12:59:44 PM

PARIS & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the initiation of a new phase II proof of concept clinical trial, evaluating the activity of tasquinimod in advanced metastatic castrate resistant prostate cancer patients. The study aims at establishing the clinical efficacy of tasquinimod used as maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy.